Prof. Valeria Santini, University of Florence Medical School, Italy, highlights novel mutational and genetic studies in MDS presented atEHA19 which might in the future translate into clinical benefits. One involves a significantly sensitive and sophisticated prognostic scoring system; another involves gene expression in MDS that may allow the classification of patients according to prognosis.
Keywords:
Myelodysplastic Syndrome (MDS)
Prof. Valeria Santini
University of Florence Medical School
Genetic studies in MDS
EHA19
Advertisement